AR124871A2 - Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes - Google Patents

Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes

Info

Publication number
AR124871A2
AR124871A2 ARP220100291A ARP220100291A AR124871A2 AR 124871 A2 AR124871 A2 AR 124871A2 AR P220100291 A ARP220100291 A AR P220100291A AR P220100291 A ARP220100291 A AR P220100291A AR 124871 A2 AR124871 A2 AR 124871A2
Authority
AR
Argentina
Prior art keywords
content
sialic acid
galactose
terminal lysine
control
Prior art date
Application number
ARP220100291A
Other languages
English (en)
Inventor
Marcel Flikweert
Charles Goochee
Francis Maslanka
Franciscus Johannes Ignatius Nagel
James Ryland
Eugene Schafer
Original Assignee
Janssen Biotech Inc
Janssen Biologics B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51528780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR124871(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Biotech Inc, Janssen Biologics B V filed Critical Janssen Biotech Inc
Publication of AR124871A2 publication Critical patent/AR124871A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

En la presente descripción se proporciona un método para producir un anticuerpo, como un anticuerpo anti-TNFa (por ejemplo, infliximab) que tiene un contenido de lisina C-terminal de aproximadamente 20% a aproximadamente 70%, y un contenido de ácido siálico de aproximadamente 1% a aproximadamente 20%, que comprende el cultivo de una célula que responde al zinc transfectada con ADN que codifica el anticuerpo en el medio de cultivo que comprende al menos 0,5 mM de zinc; y controlar la concentración de zinc en el medio de cultivo, y produce, de este modo, el anticuerpo.
ARP220100291A 2013-03-15 2022-02-14 Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes AR124871A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361791094P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR124871A2 true AR124871A2 (es) 2023-05-17

Family

ID=51528780

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP140100976A AR095660A1 (es) 2013-03-15 2014-03-13 Métodos de fabricación para el control el contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes
ARP220100291A AR124871A2 (es) 2013-03-15 2022-02-14 Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP140100976A AR095660A1 (es) 2013-03-15 2014-03-13 Métodos de fabricación para el control el contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes

Country Status (26)

Country Link
US (3) US20140273092A1 (es)
EP (1) EP2970980B2 (es)
JP (1) JP2016512029A (es)
KR (1) KR102216003B1 (es)
CN (1) CN105378086B (es)
AR (2) AR095660A1 (es)
AU (2) AU2014237635B2 (es)
BR (1) BR112015022971B1 (es)
CA (1) CA2907140A1 (es)
CY (1) CY1120980T1 (es)
DK (1) DK2970980T3 (es)
EA (1) EA201591807A1 (es)
ES (1) ES2690047T3 (es)
HR (1) HRP20181741T1 (es)
IL (1) IL240689B (es)
LT (1) LT2970980T (es)
MX (1) MX366910B (es)
PH (1) PH12015501837A1 (es)
PL (1) PL2970980T3 (es)
PT (1) PT2970980T (es)
RS (1) RS57791B1 (es)
SG (1) SG11201507577RA (es)
SI (1) SI2970980T1 (es)
TW (1) TWI630216B (es)
WO (1) WO2014149935A1 (es)
ZA (1) ZA201507671B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
CA2907140A1 (en) * 2013-03-15 2014-09-25 Janssen Biotech, Inc. Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins
BR112016002622B1 (pt) 2013-08-20 2023-04-11 Lek Pharmaceuticals D.D Meio de cultura celular e uso de selênio
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
BR112018008891A8 (pt) 2015-11-03 2019-02-26 Janssen Biotech Inc anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
CN108350416A (zh) * 2015-11-09 2018-07-31 百时美施贵宝公司 操纵在cho细胞中产生的多肽的品质属性的方法
AU2016371034A1 (en) 2015-12-17 2018-05-31 Janssen Biotech, Inc. Antibodies specifically binding HLA-DR and their uses
SG11201900746RA (en) 2016-08-12 2019-02-27 Janssen Biotech Inc Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
AU2017308734A1 (en) 2016-08-12 2019-02-14 Janssen Biotech, Inc. Fc engineered anti-TNFR superfamily member antibodies having enhanced agonistic activity and methods of using them
MX2019014576A (es) 2017-06-05 2020-07-29 Janssen Biotech Inc Anticuerpos multiespecíficos manipulados genéticamente y otras proteínas multiméricas con mutaciones asimétricas en la región ch2-ch3.
AU2018282094A1 (en) 2017-06-05 2019-12-12 Janssen Biotech, Inc. Antibodies that specifically bind PD-1 and methods of use
WO2019077628A1 (en) * 2017-10-16 2019-04-25 Council Of Scientific & Industrial Research ZINC SUPPLEMENTATION TO DECREASE GALACTOSYLATION OF RECOMBINANT GLYCOPROTEINS
EP3802607A2 (en) 2018-05-24 2021-04-14 Janssen Biotech, Inc. Monospecific and multispecific anti-tmeff2 antibodies and there uses
MX2021008030A (es) * 2018-12-31 2021-08-05 Momenta Pharmaceuticals Inc Metodos para producir ustekinumab.
CR20220025A (es) 2019-07-26 2022-05-04 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos
BR112022002540A2 (pt) 2019-08-15 2022-06-14 Janssen Biotech Inc Materiais e métodos para fragmentos variáveis de cadeia única aprimorados
MX2022011320A (es) 2020-03-13 2022-12-08 Janssen Biotech Inc Materiales y métodos para la unión de lectina tipo ig de unión a ácido siálico.
PE20230389A1 (es) 2020-05-27 2023-03-06 Janssen Biotech Inc Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas
JP2023536818A (ja) 2020-07-29 2023-08-30 ヤンセン バイオテツク，インコーポレーテツド Ｈｌａ－ｇ抗原結合ドメインを含むタンパク質及びそれらの使用
KR20230086765A (ko) 2020-10-13 2023-06-15 얀센 바이오테크 인코포레이티드 분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법
CA3199319A1 (en) 2020-10-22 2022-04-28 Janssen Biotech, Inc. Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
AU2022214491A1 (en) 2021-01-28 2023-09-14 Janssen Biotech, Inc. Psma binding proteins and uses thereof
AR125210A1 (es) 2021-03-24 2023-06-21 Janssen Biotech Inc Anticuerpos dirigidos a cd22 y cd79b
US20230040715A1 (en) 2021-03-24 2023-02-09 Janssen Biotech, Inc. Proteins comprising cd3 antigen binding domains and uses thereof
WO2023037333A1 (en) 2021-09-13 2023-03-16 Janssen Biotech, Inc CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER
WO2023046322A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceutica Nv Proteins comprising cd20 binding domains, and uses thereof
WO2023089587A1 (en) 2021-11-22 2023-05-25 Janssen Biotech, Inc. Compositions comprising enhanced multispecific binding agents for an immune response
WO2024089551A1 (en) 2022-10-25 2024-05-02 Janssen Biotech, Inc. Msln and cd3 binding agents and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
JP2647427B2 (ja) 1987-04-24 1997-08-27 帝人株式会社 被検者の病態の判定のための検出方法、モノクロ−ナル抗体および検出キット
DE10399036I1 (de) 1989-08-07 2004-04-01 Peptide Technology Ltd Bindeligande für Tumornekrosisfaktor.
US6277969B1 (en) † 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
DE07006112T1 (de) 1991-03-18 2010-01-21 New York University Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
FR2807767B1 (fr) † 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
CA2450289A1 (en) † 2003-03-20 2005-05-19 Imclone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
US20040185047A1 (en) 2003-03-21 2004-09-23 Jill Giles-Komar Anti- TNF antibodies, compositions, methods and uses
SI1807504T1 (sl) † 2004-11-02 2011-05-31 Ares Trading Sa Brezserumski celiäśni kultivacijski medij za celice sesalcev
EP2283043B1 (en) * 2008-04-07 2014-08-13 Bayer HealthCare, LLC Methods of recombinant production of glycoproteins
MY169935A (en) * 2011-04-29 2019-06-18 Biocon Biologics India Ltd "a method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof"
WO2013009648A2 (en) 2011-07-08 2013-01-17 Momenta Pharmaceuticals, Inc. Cell culture process
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
CA2907140A1 (en) * 2013-03-15 2014-09-25 Janssen Biotech, Inc. Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins

Also Published As

Publication number Publication date
TW201441263A (zh) 2014-11-01
PL2970980T3 (pl) 2019-01-31
US20160237149A1 (en) 2016-08-18
EP2970980B1 (en) 2018-08-15
ZA201507671B (en) 2017-11-29
KR102216003B1 (ko) 2021-02-16
LT2970980T (lt) 2018-10-25
RS57791B1 (sr) 2018-12-31
SI2970980T1 (sl) 2018-11-30
PT2970980T (pt) 2018-11-19
EP2970980A1 (en) 2016-01-20
BR112015022971A2 (pt) 2017-11-14
AU2020203864A1 (en) 2020-07-02
EP2970980A4 (en) 2016-09-07
JP2016512029A (ja) 2016-04-25
PH12015501837B1 (en) 2015-11-09
AU2020203864B2 (en) 2022-05-26
CA2907140A1 (en) 2014-09-25
US20220089712A1 (en) 2022-03-24
PH12015501837A1 (en) 2015-11-09
TWI630216B (zh) 2018-07-21
BR112015022971B1 (pt) 2022-05-17
ES2690047T3 (es) 2018-11-19
CY1120980T1 (el) 2019-12-11
AR095660A1 (es) 2015-11-04
CN105378086A (zh) 2016-03-02
IL240689A0 (en) 2015-10-29
EP2970980B2 (en) 2022-07-27
EA201591807A1 (ru) 2016-02-29
HRP20181741T1 (hr) 2018-12-28
DK2970980T3 (en) 2018-10-22
IL240689B (en) 2021-12-01
MX366910B (es) 2019-07-30
CN105378086B (zh) 2019-05-28
SG11201507577RA (en) 2015-10-29
US11149085B2 (en) 2021-10-19
AU2014237635B2 (en) 2020-03-12
AU2014237635A1 (en) 2015-09-03
WO2014149935A1 (en) 2014-09-25
MX2015012361A (es) 2016-04-28
US20140273092A1 (en) 2014-09-18
KR20150129025A (ko) 2015-11-18

Similar Documents

Publication Publication Date Title
AR124871A2 (es) Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes
MX2018002121A (es) Elaboracion de fosfatasas alcalinas.
MX2016004564A (es) Cultivo celular metabolicamente optimizado.
SG10201901417UA (en) Production of proteins in glutamine-free cell culture media
MY187542A (en) Carbohydrate degrading polypeptide and uses thereof
MX2019003427A (es) Composiciones para cultivo celular y metodos para la produccion de polipeptidos.
MX2016007207A (es) Metodos mejorados para la produccion de polipeptidos recombinantes.
AR095418A1 (es) Métodos para aumentar el contenido de manosa en proteínas recombinantes
AR083354A1 (es) Polipeptidos variantes cbh i (celobiohidrolasas i) con reducida inhibicion de producto
AR089324A1 (es) Composiciones, metodos y kits para la preparacion de proteinas recombinantes sialiladas
EA201590550A1 (ru) Композиции и способы получения гликопротеинов
IN2014CN03077A (es)
EA202190736A1 (ru) Способы и композиции для увеличения экспрессии белка и/или лечения расстройства, связанного с гаплонедостаточностью
AR086200A1 (es) Hongos filamentosos que tienen un fenotipo de viscosidad alterado
MY180183A (en) Methods and compositions for preventing norleucine misincorporation into proteins
MX2013012986A (es) Plantas que tienen uno o mas rasgos mejorados relacionados con el rendimento y un metodo para producirlas.
WO2012096552A3 (ko) Ｒｅｘ１을 포함하는 세포 리프로그래밍 조성물 및 이를 이용한 유도 만능줄기세포 제조방법
BR112012033396A2 (pt) Polipetídeo tendo atividade swollenin e seus usos.
MX2015010887A (es) Formulaciones y metodos para aumentar la produccion de proteinas recombinantes.
MX2013013063A (es) Plantas que tienen rasgos mejorados relacionados con el rendimiento y metodo para elaborar las mismas.
MX353243B (es) Metodo para incrementar la secrecion de proteinas recombinantes.
MX2017008633A (es) Procedimiento para preparar una proteina de fusion tnfr-fc que contiene un contenido objetivo de impurezas.
MX2019005315A (es) Produccion de particulas similares a picornavirus en plantas.
AR118125A2 (es) Péptido, composición, método para identificar células t específicas de péptido fviii, proteína de fusión y método para preparar un péptido fviii
TH162258B (th) การผลิตอนุภาคคล้ายพิคอร์นาไวรัสในพืช